Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients

被引:38
作者
Ghiorzo, P
Villaggio, B
Sementa, AR
Hansson, J
Platz, A
Nicoló, G
Spina, B
Canepa, M
Palmer, JM
Hayward, NK
Bianchi-Scarrà, G
机构
[1] Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy
[2] Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy
[3] San Martino Hosp, Dept Pathol, Genoa, Italy
[4] Karolinska Hosp & Inst, Dept Oncol Pathol, Stockholm, Sweden
[5] Natl Inst Canc Res, Genoa, Italy
[6] Queensland Inst Med Res, Brisbane, Qld 4006, Australia
基金
英国医学研究理事会;
关键词
CDKN2A/p16INK4A; mutation; immunohistochemistry; localization; familial melanoma; nevi;
D O I
10.1016/j.humpath.2003.08.017
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Little is known about the correlation between the loss of p16 expression and tumor progression in familial melanoma; no systematic study has been conducted on p16 expression in melanocytic tumors from patients carrying germline CDKN2A mutations. We analyzed 98 early primary lesions from familial patients, previously tested for germline CDKN2A status, by quantitative immunohistochemistry using 3 p16 antibodies. We found that p16 expression was inversely correlated with tumor progression and was significantly lower in melanomas,. including in situ lesions, than in nevi. Of other features analyzed, tumor thickness showed the most significant correlation with p16 levels. Lesions from mutation-negative patients displayed combined nuclear and cytoplasmic staining. However, some mutation-positive lesions (ie, G101W, 113insR, M53I, R24P, and 33ins24), including benign nevi, showed nuclear mislocalization, confirming previous studies suggesting that subcellular distribution indicates functional impairment of p16. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:25 / 33
页数:9
相关论文
共 41 条
  • [1] CDKN2A variants in a population-based sample of queensland families with melanoma
    Aitken, J
    Welch, J
    Duffy, D
    Milligan, A
    Green, A
    Martin, N
    Hayward, N
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (05): : 446 - 452
  • [2] Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
    Balch, CM
    Buzaid, AC
    Soong, SJ
    Atkins, MB
    Cascinelli, N
    Coit, DG
    Fleming, ID
    Gershenwald, JE
    Houghton, A
    Kirkwood, JM
    McMasters, KM
    Mihm, MF
    Morton, DL
    Reintgen, DS
    Ross, MI
    Sober, A
    Thompson, JA
    Thompson, JF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3635 - 3648
  • [3] Becker TM, 2001, CLIN CANCER RES, V7, P3282
  • [4] Birindelli S, 2000, INT J CANCER, V86, P255, DOI 10.1002/(SICI)1097-0215(20000415)86:2<255::AID-IJC16>3.0.CO
  • [5] 2-L
  • [6] Cachia AR, 2000, CLIN CANCER RES, V6, P3511
  • [7] A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families
    Ciotti, P
    Struewing, JP
    Mantelli, M
    Chompret, A
    Avril, MF
    Santi, PL
    Tucker, MA
    Bianchi-Scarrà, G
    Bressac-de Paillerets, B
    Goldstein, AM
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (02) : 311 - 319
  • [8] Tumor progression, early diagnosis and prognosis of melanoma
    Elder, D
    [J]. ACTA ONCOLOGICA, 1999, 38 (05) : 535 - 547
  • [9] Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene -: A comparison of four commercial antibodies
    Geradts, J
    Hruban, RH
    Schutte, M
    Kern, SE
    Maynard, R
    [J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2000, 8 (01): : 71 - 79
  • [10] GERADTS J, 1995, CANCER RES, V55, P6006